Links
- ORCID
- Crossref | PDF
- [hdl.handle.net]
- [www.ncbi.nlm.nih.gov] | PDF
- [christie.openrepository.com] | PDF
- [publications.icr.ac.uk] | PDF
- [pure.qub.ac.uk] | PDF
- [europepmc.org] | PDF
- [pure.qub.ac.uk] | PDF
Tools
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial
Journal article published in 2016 by
David Dearnaley,
Isabel Syndikus,
Helen Mossop 
,
Vincent Khoo,
Alison Birtle,
David Bloomfield,
John Graham,
Peter Kirkbride,
John P. Logue,
Zafar Malik,
Julian Money-Kyrle,
Joe M. O'Sullivan,
Miguel Panades,
Chris Parker,
Helen Patterson
and other authors.
,
Vincent Khoo,
Alison Birtle,
David Bloomfield,
John Graham,
Peter Kirkbride,
John P. Logue,
Zafar Malik,
Julian Money-Kyrle,
Joe M. O'Sullivan,
Miguel Panades,
Chris Parker,
Helen Patterson
and other authors.
Abstract
Prostate cancer might have high radiation-fraction sensitivity that would give a therapeutic advantage to hypofractionated treatment. We present a pre-planned analysis of the efficacy and side-effects of a randomised trial comparing conventional and hypofractionated radiotherapy after 5 years follow-up.